Defeating a superbug: A breakthrough in vaccine design against multidrug-resistant Pseudomonas aeruginosa using reverse vaccinology.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
10
2022
accepted:
22
07
2023
medline:
7
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Multidrug-resistant Pseudomonas aeruginosa has become a major cause of severe infections. Due to the lack of approved vaccines, this study has presented putative vaccine candidates against it. P. aeruginosa 24Pae112 as a reference strain was retrieved from GenBank database. The surface-exposed, antigenic, non-allergenic, and non-homologous human proteins were selected. The conserved domains of selected proteins were evaluated, and the prevalence of proteins was assessed among 395 genomes. Next, linear and conformational B-cell epitopes, and human MHC II binding sites were determined. Finally, five conserved and highly antigenic B-cell epitopes from OMPs were implanted on the three platforms as multi-epitope vaccines, including FliC, the bacteriophage T7 tail, and the cell wall-associated transporter proteins. The immunoreactivity was investigated using molecular docking and immune simulation. Furthermore, molecular dynamics simulation was done to refine the chimeric cell-wall-associated transporter-TLR4 complex as the best interaction. Among 6494 total proteins of P. aeruginosa 24Pae112, 16 proteins (seven OMPs and nine secreted) were ideal according to the defined criteria. These proteins had a molecular weight of 110 kDa and were prevalent in ≥ 75% of P. aeruginosa genomes. Among the presented multi-epitope vaccines, the chimeric cell-wall-associated transporter had the strongest interaction with TLR4. Moreover, the immune simulation response revealed that the bacteriophage T7 tail chimeric protein had the strongest ability to stimulate the immune system. In addition, molecular docking and molecular dynamic simulation indicated the proper and stable interactions between the chimeric cell-wall-associated transporter and TLR4. This study proposed 16 shortlisted proteins as promising immunogenic targets. Two novel platforms (e.g. cell-wall-associated transporter and bacteriophage T7 tail proteins) for designing of multi-epitope vaccines (MEVs), showed the better performance compared to FliC. In our future studies, these two MEVs will receive more scrutiny to evaluate their immunoreactivity.
Sections du résumé
BACKGROUND
Multidrug-resistant Pseudomonas aeruginosa has become a major cause of severe infections. Due to the lack of approved vaccines, this study has presented putative vaccine candidates against it.
METHODS
P. aeruginosa 24Pae112 as a reference strain was retrieved from GenBank database. The surface-exposed, antigenic, non-allergenic, and non-homologous human proteins were selected. The conserved domains of selected proteins were evaluated, and the prevalence of proteins was assessed among 395 genomes. Next, linear and conformational B-cell epitopes, and human MHC II binding sites were determined. Finally, five conserved and highly antigenic B-cell epitopes from OMPs were implanted on the three platforms as multi-epitope vaccines, including FliC, the bacteriophage T7 tail, and the cell wall-associated transporter proteins. The immunoreactivity was investigated using molecular docking and immune simulation. Furthermore, molecular dynamics simulation was done to refine the chimeric cell-wall-associated transporter-TLR4 complex as the best interaction.
RESULTS
Among 6494 total proteins of P. aeruginosa 24Pae112, 16 proteins (seven OMPs and nine secreted) were ideal according to the defined criteria. These proteins had a molecular weight of 110 kDa and were prevalent in ≥ 75% of P. aeruginosa genomes. Among the presented multi-epitope vaccines, the chimeric cell-wall-associated transporter had the strongest interaction with TLR4. Moreover, the immune simulation response revealed that the bacteriophage T7 tail chimeric protein had the strongest ability to stimulate the immune system. In addition, molecular docking and molecular dynamic simulation indicated the proper and stable interactions between the chimeric cell-wall-associated transporter and TLR4.
CONCLUSION
This study proposed 16 shortlisted proteins as promising immunogenic targets. Two novel platforms (e.g. cell-wall-associated transporter and bacteriophage T7 tail proteins) for designing of multi-epitope vaccines (MEVs), showed the better performance compared to FliC. In our future studies, these two MEVs will receive more scrutiny to evaluate their immunoreactivity.
Identifiants
pubmed: 37535697
doi: 10.1371/journal.pone.0289609
pii: PONE-D-22-29622
pmc: PMC10399887
doi:
Substances chimiques
Epitopes, B-Lymphocyte
0
Toll-Like Receptor 4
0
Epitopes, T-Lymphocyte
0
Vaccines, Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289609Informations de copyright
Copyright: © 2023 Fereshteh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Bioinformatics. 2010 Dec 1;26(23):2936-43
pubmed: 20934990
Front Immunol. 2019 Apr 24;10:781
pubmed: 31068928
J Transl Med. 2022 Sep 4;20(1):389
pubmed: 36059030
Immunity. 2010 Oct 29;33(4):530-41
pubmed: 21029963
Vaccine. 2015 May 28;33(23):2629-36
pubmed: 25882169
Bioinformatics. 2003 Jan;19(1):163-4
pubmed: 12499312
Mol Microbiol. 2000 Jul;37(2):239-53
pubmed: 10931321
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D192-6
pubmed: 15608175
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W526-31
pubmed: 15215442
J Proteome Res. 2005 Nov-Dec;4(6):2386-90
pubmed: 16335991
Comput Biol Chem. 2018 Jun;74:12-19
pubmed: 29524839
Microb Pathog. 2018 May;118:18-31
pubmed: 29524546
Am J Respir Crit Care Med. 2011 Jul 15;184(2):252-8
pubmed: 21474644
J Immunol. 2007 Jul 15;179(2):1147-54
pubmed: 17617608
Virulence. 2020 Dec;11(1):1024-1040
pubmed: 32799724
Curr Protoc Protein Sci. 2018 Apr;92(1):e53
pubmed: 30040210
Curr Protoc Immunol. 2016 Aug 01;114:18.19.1-18.19.24
pubmed: 27479659
J Bacteriol. 2006 Jan;188(1):45-54
pubmed: 16352820
Vaccine. 2018 Mar 27;36(14):1893-1900
pubmed: 29506924
Genomics. 2020 Sep;112(5):3374-3381
pubmed: 32565239
Lett Appl Microbiol. 2017 Nov;65(5):439-445
pubmed: 28857243
Biochem Mol Biol Educ. 2006 Jul;34(4):255-61
pubmed: 21638687
Brief Bioinform. 2021 Jul 20;22(4):
pubmed: 33201237
Sci Rep. 2019 Feb 21;9(1):2517
pubmed: 30792446
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
J Immunol Res. 2020 Nov 5;2020:9475058
pubmed: 33204735
Infect Immun. 2006 Feb;74(2):968-74
pubmed: 16428742
BMC Infect Dis. 2018 Oct 5;18(1):507
pubmed: 30290773
Microb Pathog. 2022 Mar;164:105425
pubmed: 35114352
Cell Mol Life Sci. 2021 Feb;78(4):1233-1261
pubmed: 33057840
FEMS Microbiol Rev. 2018 May 1;42(3):388-423
pubmed: 29547971
BMC Bioinformatics. 2007 Jan 05;8:4
pubmed: 17207271
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Sci Rep. 2016 Apr 13;6:24373
pubmed: 27071527
Sci Rep. 2021 Jan 13;11(1):1249
pubmed: 33441913
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646
pubmed: 36370105
Biomed Res Int. 2021 Sep 12;2021:1157023
pubmed: 34552981
Methods Enzymol. 1995;248:183-228
pubmed: 7674922
Sci Rep. 2019 Mar 27;9(1):5240
pubmed: 30918289
Microbiol Spectr. 2016 Feb;4(1):
pubmed: 26999395
Int J Pept Res Ther. 2022;28(2):49
pubmed: 35069055
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10
pubmed: 17517781
Vaccine. 2018 Nov 12;36(46):6926-6932
pubmed: 30314911
Microb Pathog. 2010 Jun;48(6):197-204
pubmed: 20211240
BMC Bioinformatics. 2023 Feb 24;24(1):67
pubmed: 36829109
Vaccine. 2018 Feb 14;36(8):1047-1054
pubmed: 29406241
Bioinformatics. 2005 Mar 1;21(5):617-23
pubmed: 15501914
Curr Opin Pulm Med. 2009 Mar;15(2):138-42
pubmed: 19532029
J Infect Dis. 2008 Jun 15;197(12):1717-27
pubmed: 18433330
Infect Immun. 2011 Mar;79(3):1289-99
pubmed: 21149583
Bioinformation. 2011;6(8):315-9
pubmed: 21769194
Sci Rep. 2022 Jan 7;12(1):251
pubmed: 34997046
Genomics Proteomics Bioinformatics. 2006 Feb;4(1):42-7
pubmed: 16689701
Antimicrob Agents Chemother. 2012 Jul;56(7):3826-32
pubmed: 22564848
Front Microbiol. 2011 May 27;2:117
pubmed: 21747812
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W429-32
pubmed: 17483518
Bioinformatics. 2014 Mar 15;30(6):846-51
pubmed: 24167156
Trends Parasitol. 2007 Sep;23(9):420-6
pubmed: 17656155
Proteins. 2005 Sep 1;60(4):679-89
pubmed: 16021632
Commun Biol. 2020 Oct 23;3(1):607
pubmed: 33097771
Vaccine. 2012 May 30;30 Suppl 2:B87-97
pubmed: 22607904
Surg Infect (Larchmt). 2018 Nov/Dec;19(8):757-768
pubmed: 30388058
ACM Trans Reconfigurable Technol Syst. 2010 Nov;3(4):
pubmed: 21660208
Nucleic Acids Res. 2001 Jan 1;29(1):221-2
pubmed: 11125097
Int J Mol Sci. 2020 Nov 17;21(22):
pubmed: 33212950
Infect Genet Evol. 2021 Sep;93:104982
pubmed: 34186254
Biofouling. 2014 Feb;30(2):213-22
pubmed: 24404893
Clin Microbiol Infect. 2018 Mar;24(3):258-266
pubmed: 28648860
Microorganisms. 2021 Jul 31;9(8):
pubmed: 34442726
Comput Biol Chem. 2018 Feb;72:150-163
pubmed: 29195784
Eur J Clin Microbiol Infect Dis. 2009 May;28(5):519-22
pubmed: 18949495
PLoS One. 2022 Aug 30;17(8):e0273770
pubmed: 36040920
Microb Pathog. 2023 Jul;180:106130
pubmed: 37121524
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):441-51
pubmed: 20715920
F1000 Biol Rep. 2010 May 11;2:
pubmed: 20948798
Nucleic Acids Res. 2016 Jan 4;44(D1):D286-93
pubmed: 26582926
BMC Bioinformatics. 2008 Dec 02;9:514
pubmed: 19055730